Nuria Pardo Aranda

MD,PhD Medical Oncology

[Nuria Pardo Aranda @pardo_aranda]

@audispain Ademas las clavijas del coche de carga del teléfono ambas han dejado de funcionar y son 800 euros el cambio
Un desastre.
Sin duda de coche y de atención
Para venderlo y no saber nada más de audi

[Stephen V Liu, MD @StephenVLiu]

A busy #ESMO25 warrants an episode of the @IASLC podcast, Lung Cancer Considered, to help highlight some of the new data! Watch next week for this episode with Drs. @LeXiuning @DrRiyazShah @pedrofsrocha!

[Oriol Mirallas MD @DrMirallas]

🙌🏽 Back to back sessions at #ESMO25 by @pedrofsrocha 💥

📌 DeLLphi-304 Tarlatamab 2L for #SCLC
ORR 33-37% irrespective of CFI
⬇️ Risk of death HR 0.60
☣️ Lower tox!

📌 IDeate-Lung01: intracranial activity of ifinatamab deruxtecan (IDXd)
✔️ ORR 46%

@OncoAlert
@myESMO
@_SEOM

[Stephen V Liu, MD @StephenVLiu]

Congratulations to the winner of the @IASLC 2025 Daniel C. Ihde Lectureship Award for Medical Oncology at #WCLC25 - Dr. @HendriksLizza - who reminds us of the need to rethink trial eligibility to answer relevant questions and to make lung cancer research sustainable.

[Jordi Remon @JordiRemon]

HARMONi: Ivonescimab+CT ⬆️ PFS vs CT in post-osi EGFRm NSCLC.Qx:
-How and when to place this strategy based new SoC 1st line?
-Control arm trial was CT not CT+Ami
-Data support Ivonescimab in EGFRm (table)
-What EGFRm obtain higher benefit of IVO? Predictive biomarkers
#WCLC2025

[Stephen V Liu, MD @StephenVLiu]

Chemotherapy duration shown here - and fairly high crossover rates are reassuring. More toxicity, yes, but no new signals seen here. Question remains - which regimen for which patient? But a very welcome advance and impressive presentation from @dplanchard at #WCLC25.

[Jordi Remon @JordiRemon]

FLAURA2 trial: Osi + CT improves PFS & OS (⬇️ 23% risk death) vs Osi alone in mEGFR NSCLC. Qx:
-Intensification for all pts? Benefit in some subgroups only (Brain)
-Chemo or ami for intensification?toxicity QoL, relevant for decisions
-Cost
-Is Osi alone no more valid?
#WCLC2025

[Jordi Remon @JordiRemon]

PECATI Trial,lenvatinib plus pembrolizumab (20/200) a potential ttx for pts w metastatic pretreated B3-Thymoma or TC
-mPFS 14.9mo
-ORR: 23.3%
-1-y OS: 85.2%
-G3 irAEs: 14%
-Keep Dose intensity lenva first 8 weeks ⬆️ PFS
Thanks to all authors!!
DOI: 10.1016/S1470-2045(25)00300-6

[Oriol Mirallas MD @DrMirallas]

🤩 Thanks for passing by, photos with both #phaseI and #thoracic group at @VHIO

Interesting work presented at the #drugdevelopment poster session 🔥

🙌🏽 An incredible #ASCO25 @ASCO
@OncoAlert @myESMO @_SEOM
#OncoNexion25

[Oriol Mirallas MD @DrMirallas]

#ASCO25

Day2: Poster session #GI and #lungcancer

@VHIO representation @ASCO 🙌🏽🎉

#OncoNexion25 @_SEOM

@myESMO @OncoAlert @OncBrothers

[Oriol Mirallas MD @DrMirallas]

💥 Overview of #NSCLC after #ESMO24 🙌🏽

Organized by @EnriquetaFelip @EnriquetaFelip

🎉👏🏽Congratulations to all my colleagues for the brilliant speeches

🙏🏽 Thanks for the kind invitation

#lungcancer #Oncology

[Oriol Mirallas MD @DrMirallas]

#ESMO24
🫁 Track #Barcelona auditorium
🪑 @BenjaminBesseMD
👉🏽GALAXIES-LUNG201: Belrestotug+Dostarlimab ORR 65.6%
No PFS
👉🏽RELATIVITY-104: Nivo vs Nivo+Rela
❌ITT: PFS 8.8m, ORR 46%
✔️ ADK+PDL1>1%(non-planned) PFS 9.8 vs 5.5ma. ORR 60.7%
👏🏼🙌🏽 Great discussion @GarassinoMarina

[Jarushka Naidoo @DrJNaidoo]

Sotorasib is a Pan-RASG12C-, with activity in NRASG12C+ cancers ⁦@CD_AACR⁩:

- sotorasib 5x ⬆️potent against NRASG12C vs KRASG12C or HRASG12C (activity in all)
- pt w NRASG12C+ CRC had prolonged response to soto+panitumumab

⁦@OncoAlert⁩ #LCSM https://t.co/bowOYELJVJ

[Oriol Mirallas MD @DrMirallas]

#SEOM22
Revisión del tratamiento de #cabezaycuello #HNSCC por Dra. Basté
📌 Sala Castilla
🕖 19:00h
@_SEOM
👇🏼

[Nuria Pardo Aranda @pardo_aranda]

@La_SER @manusola_soles dimisión

[Nuria Pardo Aranda @pardo_aranda]

@epr82 @_Vila_L @VHIO muchas gracias eli!!ya vi que tu tambien hace poco!!congrats!!

[Nuria Pardo Aranda @pardo_aranda]

@AhernandoCalvo @_Vila_L @VHIO ei!!!muchas gracias!!!como vas???me han dicho que vuelves!!!

[Nuria Pardo Aranda @pardo_aranda]

@_Vila_L @VHIO gracias!!!

[Jordi Remon @JordiRemon]

Luckily 2021 = Relevant year 💥 for new treatment approvals in aNSCLC🫁 (some approved in early stage). For 2022 📕✏️: not need more “me too” drugs⛔️; need new agents at the time of PD based on resist mechanisms (not easy!!) & less inequities (fig. not perfect!) @OncoAlert #LUNG

[Jordi Remon @JordiRemon]

Immunotherapy works in almost all thoracic malignancies including MPM 👏🏻👏🏻. Its role in thymic malignancies (rare and orphan) deserves further evaluation despite NIVOTHYM trial reported meaningful clinical data. Good for having clinical trials ongoing #ESMO21 @OncoAlert